Orionis Biosciences develops conditionally acting medicines using its A-KINE® and ALLO-GLUE™ platforms, which leverage targeted cytokine immunotherapies and allosteric molecular glues to enhance immune responses against cancer and other diseases. The company addresses the challenge of treating solid tumors by advancing its first-in-class reprogrammed interferon cytokine, ORB-011, currently in Phase 1 clinical trials.
Funding
$85.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CAFounders
Product
Problem
Existing cancer treatments often struggle to effectively target solid tumors and stimulate a robust immune response within the tumor microenvironment. Traditional cytokine therapies lack precise targeting, leading to systemic toxicities and limited efficacy in activating the immune system specifically at the tumor site. This necessitates innovative approaches to enhance immune responses against cancer while minimizing off-target effects.
Solution
Orionis Biosciences is developing conditionally acting medicines using its A-KINE® and ALLO-GLUE™ platforms to address the challenges of treating cancer and other diseases. The A-KINE® platform creates cytokine-based biologics with enhanced in vivo cell target selectivity compared to traditional cytokine modalities, enabling controlled immune system activation. The ALLO-GLUE™ platform utilizes monovalent, drug-like small molecules that act as allosteric molecular glues, accessing historically undruggable and new disease targets by modulating protein degradation. These platforms enable the development of targeted immunotherapies and molecular glue drugs designed to enhance immune responses against cancer with greater precision and reduced toxicity.
Target Audience
The primary target audience includes patients with advanced solid tumors and other diseases, as well as pharmaceutical companies seeking innovative drug modalities for cancer immunotherapy and targeted protein degradation.
Features
- A-KINE® platform: Cytokine-based biologics with superior in vivo cell target selectivity.
- ALLO-GLUE™ platform: Monovalent, drug-like small molecules acting as allosteric molecular glues.
- Target-agnostic approach to molecular glue design.
- ORB-011: First-in-class reprogrammed interferon cytokine in Phase 1 clinical trials for advanced solid tumors.
- Designed to restart a stalled cancer immunity cycle.